LoginSignup
APD

BNB Plus Corp.

Stock
Stock
Ticker: APDN
APDN

Price

Price

CHART BY

Frequently asked questions

The market capitalization of BNB Plus Corp. is $896.18K. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
BNB Plus Corp.'s Earnings Per Share (EPS) over the trailing twelve months (TTM) is -6.506. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover BNB Plus Corp.'s stock, with a consensus target price of $1,125.00. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, BNB Plus Corp. reported a revenue of $2.39M.
BNB Plus Corp.'s Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$20.60M. EBITDA measures the company's overall financial performance.
BNB Plus Corp. has a free cash flow of -$11.95M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
BNB Plus Corp. employs approximately 26 people. It operates in the Financials sector, specifically within the Biotechnology industry.
The free float of BNB Plus Corp. is 4.52M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$896.18K
EPS (TTM) 
-6.506
Free Float 
4.52M
Revenue (TTM) 
$2.39M
EBITDA (TTM) 
-$20.60M
Free Cashflow (TTM) 
-$11.95M

Analyst Ratings

The price target is $1,125.00 and the stock is covered by 1 analysts.

Buy

0

Hold

1

Sell

0

Information

BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Employees
26
Industries
Biotechnology
Sector
Financials

Identifier

Primary Ticker
APDN

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin